Literature DB >> 31030972

NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma.

Zuzana Strizova1, Pavla Taborska1, Dmitry Stakheev1, Simona Partlová1, Klara Havlova2, Stepan Vesely2, Jirina Bartunkova1, Daniel Smrz3.   

Abstract

OBJECTIVES: Renal cell carcinoma (RCC) is the most lethal urologic malignancy with increasing incidence worldwide. The conventional treatment strategies for advanced or recurrent RCC are not efficient and show considerable toxicities. Adoptive cell transfer (ACT) has become a promising treatment option for multiple cancers, particularly in combination with other therapeutic approaches. ACT often utilizes extensively in vitro expanded tumor-infiltrating lymphocytes (TILs). However, TILs are a very heterogeneous mix of cell populations and only those populations that have a cytotoxic and migratory potential are thought to deliver a therapeutic impact in ACT. The identification and localization of these therapeutically potent populations are therefore needed. METHODS AND MATERIALS: A total number of 57 tissue samples from 19 RCC patients who underwent radical nephrectomy was analyzed. The tissue samples were obtained from the tumor, peritumoral tissue, and the adjacent healthy renal tissue. The tissues were sliced, enzymatically dissociated into single cell suspensions and the obtained cells further analyzed by flow cytometry for the expression of markers of lymphocyte cytotoxicity - TRAIL and FasL, and a surrogate marker of lymphocyte migratory activity - PECAM-1. The analyzed data were next correlated with the clinical and histopathological data.
RESULTS: Non-clear cell RCC (non-ccRCC) tumors showed a significantly decreased tumor infiltration with TRAIL+FasL+ NK cells but elevated infiltration with FasL+PECAM-1+ T cells as compared with clear cell RCC (ccRCC) tumors. Further analyses revealed that the peritumoral tissue of ccRCC patients is a reservoir of TRAIL+FasL+, TRAIL+PECAM-1+, or FasL+PECAM-1+ NK and T cells.
CONCLUSIONS: The cytotoxic/migratory lymphocytes were identified in tumors of ccRCC patients. These lymphocytes became excluded from the tumor and accumulated in the patient's peritumoral tissue.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FasL; PECAM-1; Renal cell carcinoma; TRAIL; Tumor-infiltrating lymphocytes; peritumoral

Year:  2019        PMID: 31030972     DOI: 10.1016/j.urolonc.2019.03.014

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

1.  Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment.

Authors:  Mohammad Reza Haghshenas; Nasrollah Erfani; Sajjad Gerdabi; Fatemeh Asadian; Razie Kiani; Bijan Khademi
Journal:  Head Neck Pathol       Date:  2022-09-28

Review 2.  Natural killer cell homing and trafficking in tissues and tumors: from biology to application.

Authors:  Guang He Ran; Yu Qing Lin; Lei Tian; Tao Zhang; Dong Mei Yan; Jian Hua Yu; You Cai Deng
Journal:  Signal Transduct Target Ther       Date:  2022-06-29

Review 3.  Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art.

Authors:  Michele Marchioni; Juan Gomez Rivas; Anamaria Autran; Moises Socarras; Simone Albisinni; Matteo Ferro; Luigi Schips; Roberto Mario Scarpa; Rocco Papalia; Francesco Esperto
Journal:  Curr Urol Rep       Date:  2021-04-22       Impact factor: 3.092

4.  Tumoral and paratumoral NK cells and CD8+ T cells of esophageal carcinoma patients express high levels of CD47.

Authors:  Zuzana Strizova; Jiri Vachtenheim; Martin Snajdauf; Robert Lischke; Jirina Bartunkova; Daniel Smrz
Journal:  Sci Rep       Date:  2020-08-18       Impact factor: 4.379

5.  Development and Validation of a Radiomic Nomogram for Predicting the Prognosis of Kidney Renal Clear Cell Carcinoma.

Authors:  Ruizhi Gao; Hui Qin; Peng Lin; Chenjun Ma; Chengyang Li; Rong Wen; Jing Huang; Da Wan; Dongyue Wen; Yiqiong Liang; Jiang Huang; Xin Li; Xinrong Wang; Gang Chen; Yun He; Hong Yang
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.